Navigating Skin Toxicities from Targeted Cancer Therapies: A Dermatological Perspective

Targeted cancer therapies have revolutionized oncology, offering more effective treatment options for various malignancies. However, their use is often accompanied by a range of cutaneous toxicities that pose unique challenges for dermatologists. Understanding these toxicities and their management is crucial for optimizing patient care. Understanding Skin Toxicities Skin toxicities resulting from targeted therapies can range from mild rashes to severe dermatitis and can significantly impact a patient’s quality of life and treatment adherence. Common skin toxicities include: Rash: Eruptions commonly associated with tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib. Hand-foot syndrome: Palmar-plantar erythrodysesthesia often seen with agents like capecitabine and docetaxel. Photosensitivity: Increased sensitivity to sunlight, frequently seen with agents such as vemurafenib. Dry skin and pruritus: Commonly reported with various targeted therapies, leading to discomfort and potential treatment interruptions. Mechanisms Behind Skin Toxicities The mechanisms of these skin toxicities can vary. Many targeted therapies affect signaling pathways crucial for cell proliferation and survival, leading to dysregulation and resultant skin manifestations. For instance, inhibitors targeting the EGFR pathway are known to interfere with keratinocyte function, leading to epidermal fragility and rash. Management Strategies Effective management of skin toxicities is essential to ensure patient comfort and adherence to oncology treatments. The following strategies are recommended: Patient Education: Informing patients about potential skin toxicities prior to treatment can prepare them for what to expect and facilitate early recognition. Topical Treatments: For mild to moderate rashes, topical corticosteroids and emollients may provide symptom relief. In cases of hand-foot syndrome, urea-based creams can help maintain skin hydration. Systemic Treatments: For more severe rash